Novel therapeutics for the treatment of asthma

Bibliography

• ELIAS JA, ZHU Z, CHUPP G, HOMER RJ: Airway remodel-ling in asthma. J. Clin. Invest. (1999) 104: 1001–1006.
   Google Scholar
• HOLGATE ST, WILSON JR, HOWARTH PH: New insightsinto airway inflammation by endobronchial biopsy. Am. Rev. Resp. Dis. (1992) 145:S2–S6.
   PubMed Web of Science ®Google Scholar
• O'BYRNE PM, POSTMA DS: The many facets of airwayinflammation; asthma and chronic obstructive pulmonary disease. Am. J. Respir. Grit. Care Med. (1999) 159:S42–S66.
   Google Scholar
• BARNES PJ, PEDERSEN S, BUSSE WW: Efficacy and safety of inhaled corticosteroids; new developments. Am. J Respir. Grit. Care Med. (1998) 1 5 7:S1–S53.
   Google Scholar
• ••This is an excellent review describing the clinical use ofsteroids in asthma and the basic biology underlying their mechanism of action.
   Google Scholar
• HOLGATE ST: The epidemic of allergy and asthma. Nature (1999) 402 (Suppl.):B2–B5.
   Google Scholar
• BARNES PJ: Therapeutic strategies for allergic disease. Nature (1999) 402 (Suppl.):B31–B37.
   Google Scholar
• ••This review describes current therapeutic strategies for thetreatment of allergy.
   Google Scholar
• WEISS KB, GERGEN PJ, HODGSON TA: An economic evaluation of asthma in the United States. N Engl. J. Med. (1992) 326:862–868.
   PubMed Web of Science ®Google Scholar
• •Although dated, this paper is a thorough examination of the medical and social costs of asthma.
   Google Scholar
• BARNES PJ, JONSSON B, KLIM JB: The costs of asthma. Eur. Resp. J. (1996) 9:636–642.
   PubMed Web of Science ®Google Scholar
• DRAZEN JM, ISRAEL E, O'BYRNE PM: Treatment of asthma with drugs modifying the leukotriene pathway. N Engl. J. Med. (1999) 340:197–206.
   PubMed Web of Science ®Google Scholar
• ••This is an outstanding review which describes the currentstatus of leukotriene inhibitors in the treatment of asthma.
   Google Scholar
• ABBAS AK, MURPHY KM, SHER A: Functional diversity of helper T lymphocytes. Nature (1996) 383:787–793.
   PubMed Web of Science ®Google Scholar
• •A well written review describing the concept of the Thl and Th2 cell.
   Google Scholar
• O'GARRA A: Cytokines induce the development of functionally heterogeneous T helper cell subsets. Cell (1998) 8:275–283.
   Google Scholar
• CHANTRY D: Tumor necrosis factor antagonists. Emerging Drugs (1999) 4:5–13.
   Google Scholar
• PRETE GD: The concept of type-1 and type-2 helper T cells and their cytokines in humans. Inter. Rev. Immunol. (1998) 16:427–455.
   PubMedGoogle Scholar
• •A review of Thl and Th2 cells and their role in human disease.
   Google Scholar
• AEBISCHER I, STADLER BM: Th2 cells in allergic responses at the limits of the concept. Adv. Immunol. (1996) 61:341–403.
   PubMed Web of Science ®Google Scholar
• BENTLEY AM, MENG Q, ROBINSON DS, et al.: Increases in activated T lymphocytes, eosinophils and cytokine mRNA expression for interleukin-5 and granulo-cyte/macrophage colony-stimulating factor in bronchial biopsies after allergen inhalation challenge in atopic asthmatics. Am. J. Respir. Cell Mol. Biol. (1993) 8:35–42.
   PubMed Web of Science ®Google Scholar
• COHN L, HOMER RJ, MARINOV A, RANKIN J, BOTTOMLYK: Induction of airway mucus production by Thelper 2 (Th2) cells: a critical role for interleukin 4 in cell recruitment but not mucus production. J Exp. Med. (1997) 186:1737–1747.
   PubMed Web of Science ®Google Scholar
• WILLS-KARP M, GAVETT SH, SCHOFIELD B, FINKELMANF: Role of interleukin-4 in the development of allergic airway inflammation and airway hyperresponsive-ness. Adv. Exp. Med. Biol. (1996) 409:343–347.
   PubMedGoogle Scholar
• WILLS-KARP M, LUYIMBAZI J, XU X, et al.: Interleukin-13:central mediator of allergic asthma. Science (1998) 282:2258–2261.
   PubMed Web of Science ®Google Scholar
• ADKINSON NF: Immunotherapy for allergic rhinitis. N Engl. J. Med. (1999) 341:522–524.
   PubMed Web of Science ®Google Scholar
• MILGROM H, FICK RB, SU JQ, et al.: Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl. J. Med. (1999) 341:1966–1973.
   PubMed Web of Science ®Google Scholar
• JARDIEU PM, FICK RB: IgE inhibition as a therapy for allergic disease. Int. Arch. Alter. Immunol. (1999) 1 1 8:112–115.
   Google Scholar
• •A review of anti-IgE therapy.
   Google Scholar
• EGAN RW, UMLAND SP, CUSS FM, CHAPMAN RW: Biology of interleukin-5 and its relevance to allergic disease. Allergy (1996) 2:71–81.
   Google Scholar
• EGAN RW, ATHWAL D, BODMER MW, et al.: Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. Arzneimittelforschung (1999) 9:779–790.
   Google Scholar
• TEMANN UA, GEBA GP, RANKIN JA, FLAVELL RA: Expres-sion of interleukin-9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia and bronchial hyperreactivity. J. Exp. Med. (1998) 188:1307–1320.
   PubMed Web of Science ®Google Scholar
• LEVITT RC, MCLANE MP, MACDONALD D, et al.: IL-9 pathway in asthma: new therapeutic targets for allergic inflammatory disorders. J. Allergy Clin. Immunol. (1999) 103:S485–491.
   PubMed Web of Science ®Google Scholar
• NICOLAIDES NC, HOLROYD KJ, EWART SL, et al.: Interleukin 9: a candidate gene for asthma. Proc. Nati Acad. Sci. USA (1997) 94:13175–13180.
   PubMed Web of Science ®Google Scholar
• ZURAWSKI G, DE VRIES J: Interleukin 13, an interleukin-4 like cytokine that acts on monocytes and B cells but not on T cells. Immunol Today (1994) 15:19–26.
   PubMedGoogle Scholar
• ZURAWSKI SM, VEGA F, HUYGIE B, ZURAWSKI G: Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO J (1993) 12:3899–3905.
   Google Scholar
• •An important paper describing the similarities in the signal transduction pathways of IL-4 and IL–13.
   Google Scholar
• WILLS-KARP M: Immunological basis for antigen induced airway hyperresponsiveness. Ann. Rev. Immunol. (1999) 17:255–281.
   PubMed Web of Science ®Google Scholar
• •An excellent review of the basic biology of asthma.
   Google Scholar
• LUKACS NW, OLIVEIRA SHP, HOGABOAM CM: Chemokines and asthma: redundancy or coordinated effort. J. Clin. Invest. (1999) 104:995–999.
   PubMed Web of Science ®Google Scholar
• DAUGHERTY BL, SICILIANO SJ, DEMARTINO JA, et al.:Cloning, expression and characterization of the human eosinophil eotaxin receptor. J Exp. Med. (1996) 183:2349–2345.
   PubMed Web of Science ®Google Scholar
• SALLUSTO F, MACKAY CR, LANZAVECCHIA A: Selectiveexpression of the eotaxin receptor CCR3 by human T helper 2 cells. Science (1997) 277:2005–2007.
   PubMed Web of Science ®Google Scholar
• SALLUSTO F, LENIG D, MACKAY CR, LANZAVECCHIA A: Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J. Exp. Med. 187:875–883.
   PubMedGoogle Scholar
• •An important paper describing differential chemokine receptor expression by T-cell subsets.
   Google Scholar
• D'AMBROSIO D, IELLEM A, BONECCHI R, et al.: Selective upreg-ulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human Type 2 Th cells. J. Immune]. (1998) 161:5111–5115.
   PubMed Web of Science ®Google Scholar
• •An important paper describing differential chemokine receptor expression by T-cell subsets.
   Google Scholar
• GIEMBYZ MA: Phosphodiesterase inhibitors and the treatment of asthma; where are we now and where do we go from here. Drugs (2000) 59:193–212.
   PubMed Web of Science ®Google Scholar
• •An up-to-date review of PDE4 inhibitors.
   Google Scholar
• RAY A, COHN L: Th2 cells and GATA-3 in asthma: new insights into the regulation of airway inflammation. J. Clin. Invest. (1999) 104:985–993.
   PubMed Web of Science ®Google Scholar
• FOWELL DJ, SHINKAI K, LIAO XC, et al.: Impaired NFATc translocation and failure of Th2 development in Itk-deficient CD4+ T cells. Immunity (1999) 4:399–409.
   Google Scholar